4X

GHRP-2 and Ipamorelin are both synthetic peptides investigated as GHSR-1a agonists, sharing the ability to stimulate growth hormone release from pituitary somatotrophs via ghrelin receptor–coupled pathways. Tauber et al. (1993) characterized GHRP-2-stimulated GH secretion in a pediatric research cohort with confirmed growth hormone deficiency, examining peak GH responses in plasma. Pihoker et al. (1995) examined intranasal GHRP-2 and GH secretion patterns in a study population with short stature. Laferrère et al. (2002) conducted a direct comparison of GHRP-2 and GHRH in GH reserve assessment assays, characterizing pituitary responsiveness to both secretagogue types in adult subjects. Reviews (Ishida et al., 2020; Sinha et al., 2020) describe Ipamorelin's GHSR-1a selectivity profile relative to other GH secretagogues, including its differential effect on non-GH endocrine endpoints such as cortisol and prolactin. Tesamorelin, a GHRH receptor agonist rather than a GHSR-1a agonist, engages the pituitary GH axis through a distinct upstream mechanism; its pharmacology within the broader class of GH-axis peptides has been surveyed in the Ishida et al. (2020) review.

A body of clinical research has examined Tesamorelin in study populations with HIV-associated lipodystrophy, a condition characterized by excess visceral adipose tissue accumulation in HIV-positive individuals on antiretroviral therapy. Falutz et al. (2007) conducted a randomized controlled study assessing Tesamorelin alongside measurement of visceral adipose tissue, lipid markers, and other metabolic parameters in an HIV-positive cohort. A pooled analysis of two Phase 3 studies (Falutz et al., 2010) examined changes in abdominal adiposity measurements and metabolic biomarker profiles across a combined dataset. Mamputu et al. (2012) analyzed correlations between visceral adipose tissue measurements and metabolic parameter trajectories within clinical study populations. These studies collectively characterize Tesamorelin's pharmacological profile in the context of GH axis modulation and its downstream metabolic effects as measured in controlled research populations.

MGF is an IGF-1 splice variant generated in skeletal muscle under mechanical loading conditions. Yang and Goldspink (2002) examined IGF-1 gene expression — including the MGF isoform — in mechanically overloaded skeletal muscle, characterizing splice-variant expression dynamics in response to loading stimuli. Dluzniewska et al. (2005) studied the C-terminal MGF peptide in a rodent brain ischemia model, examining neuronal survival endpoint measures in that preclinical system. Zhang et al. (2023) reviewed the research literature on MGF in chondrocyte biology and cartilage defect models, surveying molecular evidence on MGF's involvement in cartilage tissue research contexts. Goldspink (2010) provided a mechanistic minireview contextualizing MGF as an IGF-1 gene product in tissue biology research, discussing experimental evidence relating MGF expression to satellite cell activity in skeletal muscle systems. The 24-amino-acid sequence of the MGF E-peptide (YQPPSTNKNTKSQRRKGSTFEEHK) is central to its distinct pharmacological profile relative to full-length IGF-1.

Ipamorelin's GHSR-1a activity extends to enteric neuromuscular pathways, and several studies have examined its effects on gastrointestinal motility endpoints. Mosińska et al. (2017) reviewed ghrelin receptor agonist pharmacology in gastrointestinal motility research, characterizing the mechanistic basis for gastrointestinal motility profiles observed in preclinical systems within this compound class. Venkova et al. (2009) used a rodent model of postoperative ileus to examine Ipamorelin's effect on gastric contractility and motility parameters in that experimental system. Beck et al. (2014) conducted a prospective, randomized, controlled proof-of-concept clinical study (NCT00672074) in bowel resection patients, assessing gastrointestinal function endpoints following surgery.